Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...

We’re not gonna lay down ... You’re never going to look at our heart and say, we ain’t ready to play. I don’t coach that way, and I don’t recruit guys (who are) that way.” ...

In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – Research ...

Marcus Webb made Goldenseal one of Knoxville's first specialized high school football postgame cleaning companies.

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Etrumadenant is under clinical development by Arcus Biosciences and currently in Phase II for Metastatic Colorectal Cancer.

HAYWARD, Calif., December 19, 2024--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike due to its ...

HAYWARD, Calif., December 24, 2024--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...

Arcus Biosciences Stock Performance NYSE:RCUS opened at $15.46 on Friday. The company’s 50-day moving average is $16.41 and its two-hundred day moving average is $16.06. Arcus Biosciences, Inc ...

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike due to its ...